Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ripasudil after cataract surgery and descemetorhexis in Fuchs endothelial corneal dystrophy
NCT05826353Phase 3Completed
- Start
- May 2023
- Primary completion
- Jan 2025
- Modality
- Small Molecules
- Countries
- 6
01
Overview
A Phase 3 trial of ripasudil in Fuchs endothelial corneal dystrophy (FECD). Started May 2023; status: completed.
02
Drugs
ripasudil
03
Conditions
Fuchs endothelial corneal dystrophy (FECD)
Beyond the preview
Go deeper on NCT05826353.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05826353.